Although biologic therapies targeting IL-4/IL-13 (e.g., dupilumab) have significantly advanced the treatment of AD, many patients with moderate-to-severe disease have an incomplete response or contraindications to biologics [7]. This evidence concerns the gene IL13 and Alzheimer disease.